Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gh Research Plc (NQ: GHRS )

11.78 +0.10 (+0.86%)
Streaming Delayed Price Updated: 3:49 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,874
Open 12.30
Bid (Size) 11.78 (3)
Ask (Size) 11.84 (1)
Prev. Close 11.68
Today's Range 11.52 - 12.30
52wk Range 5.050 - 14.64
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+120.19%
+120.19%
1 Month
+5.75%
+5.75%
3 Month
+55.41%
+55.41%
6 Month
+44.90%
+44.90%
1 Year
+32.21%
+32.21%

More News

Read More
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
GH Research: Q4 Earnings Insights
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
Via Talk Markets
Exposures Product Safety
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
Via Talk Markets
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
Via Benzinga
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Via Talk Markets
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
Via Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Via Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Via Benzinga
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
From GH Research PLC
Via GlobeNewswire
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
Via Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Via Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Via Benzinga
Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.